Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.91 USD

12.91
679,229

+0.37 (2.95%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $12.97 +0.06 (0.46%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ENTA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Enanta Pharmaceuticals, Inc. [ENTA]

Reports for Purchase

Showing records 21 - 40 ( 164 total )

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 21

05/11/2022

Company Report

Pages: 7

FY2Q22 Update - Strong Cash & Catalysts, but Lowering PT to $70 PT

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 22

02/15/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 23

02/14/2022

Company Report

Pages: 7

FY1Q22 Update - Topline RSV Data in 2Q2022, with More Pipeline Progress

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 24

01/13/2022

Company Report

Pages: 6

Pipeline Progressing With Focus on RSVP Study Readout in 2Q2022

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 25

01/13/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 26

11/24/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 27

11/23/2021

Company Report

Pages: 8

FY2021 Update - Lowering Our PT to $101 But Key 2022 Catalysts Ahead

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 28

10/20/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 29

10/19/2021

Company Report

Pages: 6

EDP-235, an Oral Anti-Viral for SARSCoV2 to Enter the Clinic in 2022

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 30

10/05/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 31

10/05/2021

Company Report

Pages: 6

NASH Studies to be Stopped but Programs Still to be Used in Combos

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 32

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ENTA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 33

08/09/2021

Daily Note

Pages: 3

MORNING & MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 34

08/06/2021

Company Report

Pages: 6

FY3Q21 Update - Multiple 2021 and 2022 Catalysts Ahead

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 35

07/12/2021

Daily Note

Pages: 27

2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 75.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 36

06/24/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 37

06/23/2021

Company Report

Pages: 6

Data on EDP-721 & EDP-514 Show Progress Toward HBV Triple-Combo

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 38

06/03/2021

Industry Report

Pages: 3

Healthcare -Virtual Analyst Marketing

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 39

05/10/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Enanta Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 40

05/07/2021

Company Report

Pages: 6

FY2Q21 Update - Pipeline Remains Undervalued w/ Multiple Catalysts Ahead

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party